Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Lena Schroeder, Michael Fuchs, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2016) 128 (22): 922.

https://doi.org/10.1182/blood.V128.22.922.922

Published: 2016

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

Journal Articles

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Dennis A. Eichenauer, MD, Helen Goergen, Annette Pluetschow, Karolin Behringer, MD, Stefanie Kreissl, MD, Paul Bröckelmann, MD, Michael Fuchs, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2015) 126 (23): 2729.

https://doi.org/10.1182/blood.V126.23.2729.2729

Published: 2015

Journal Articles

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Bastian von Tresckow, MD, Annette Pluetschow, Heinz Haverkamp, Vladan Vucinic, MD, Andreas Rank, MD, Max S. Topp, MD, Michaela Feuring-Buske, MD, Carsten Kobe, MD, Georg Kuhnert, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 4433.

https://doi.org/10.1182/blood.V124.21.4433.4433

Published: 2014

Journal Articles

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Michael Fuchs, MD, Karolin Behringer, MD, Boris Böll, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2014) 124 (21): 3058.

https://doi.org/10.1182/blood.V124.21.3058.3058

Published: 2014

Journal Articles

Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials

Boris Böll, MD, Karolin Behringer, MD, Helen Görgen, Paul Bröckelmann, MD, Bastian von Tresckow, MD, Dennis A. Eichenauer, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 3062.

https://doi.org/10.1182/blood.V124.21.3062.3062

Published: 2014

Journal Articles

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Achim Rothe, MD, Stephanie Sasse, MD, Max S. Topp, MD, Dennis A. Eichenauer, MD, Bastian von Tresckow, MD, Horst-Dieter Hummel, MD, Miroslav Ravic, MD PhD, Jens-Peter Marschner, MD, Andreas Engert, MD

Blood (2014) 124 (21): 1753.

https://doi.org/10.1182/blood.V124.21.1753.1753

Published: 2014

Journal Articles

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Plütschow, PhD, Stefanie Kreissl, MD, Michael Fuchs, MD, Martin Soekler, MD, Nicole Engel, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4344.

https://doi.org/10.1182/blood.V122.21.4344.4344

Published: 2013

Journal Articles

Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials

Bastian von Tresckow, MD, Helen Görgen, Annette Plütschow, PhD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Achim Rothe, MD, Michael Fuchs, MD, Karolin Behringer, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2013) 122 (21): 4231.

https://doi.org/10.1182/blood.V122.21.4231.4231

Published: 2013

Journal Articles

Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials

Bastian von Tresckow, MD, Heinz Haverkamp, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2013) 122 (21): 637.

https://doi.org/10.1182/blood.V122.21.637.637

Published: 2013

Journal Articles

Systematic Review and Individual Patient Data Meta-Analysis Of Treatment-Related Risk Of Secondary Malignant Neoplasms After Hodgkin Lymphoma

Jeremy Franklin, PhD, Dennis A. Eichenauer, MD, Ingrid Becker, MSc, Andreas Engert, MD

Blood (2013) 122 (21): 1753.

https://doi.org/10.1182/blood.V122.21.1753.1753

Published: 2013

Journal Articles

A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

Bastian von Tresckow, MD, Aleksander Skotnicki, MD, PhD, Igur Lisukov, MD, Shivani Srivastava, MD, David S. Morgan, MD, Franck Morschhauser, MD, PhD, Caterina Stelitano, Jeffrey Szer, BMedSc, MBBS, FRACP, Dennis A. Eichenauer, MD, Jeremy S. Abramson, MD, Anna Sureda, MD, PhD, Christophe Ferme, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4648.

https://doi.org/10.1182/blood.V122.21.4648.4648

Published: 2013

Journal Articles

German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients

Boris Böll, MD, Annette Plütschow, PhD, Michael Fuchs, MD, Dennis A. Eichenauer, MD, Indra Thielen, MD, Bastian von Tresckow, MD, Karolin Behringer, MD, Johannes Atta, Michael Pfreundschuh, Prof, MD, Michaela Feuring-Buske, MD, Martin Vogelhuber, MD, Martin Sökler, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2013) 122 (21): 3054.

https://doi.org/10.1182/blood.V122.21.3054.3054

Published: 2013

Journal Articles

A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Eugene Zhukovsky, PhD, Achim Rothe, MD, Bastian von Tresckow, MD, Max Topp, Anas Younes, MD, Dennis A. Eichenauer, MD, Horst Hummel, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Joerg Kessler, PhD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Poggevon Strandmann, PhD, Andreas Engert, MD

Blood (2013) 122 (21): 5116.

https://doi.org/10.1182/blood.V122.21.5116.5116

Published: 2013

Journal Articles

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Bastian von Tresckow, MD, Horst Müller, PhD, Dennis A. Eichenauer, MD, Jan Peter Glossmann, MD, Andreas Josting, MD, Boris Böll, MD, Beate Klimm, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2012) 120 (21): 2633.

https://doi.org/10.1182/blood.V120.21.2633.2633

Published: 2012

Journal Articles

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Achim Rothe, MD, Stephanie Sasse, MD, Helen Goergen, Dennis A. Eichenauer, MD, Andreas Lohri, MD, Ulrich Jäger, Christopher Bangard, Andreas Engert, MD

Blood (2012) 120 (21): 2743.

https://doi.org/10.1182/blood.V120.21.2743.2743

Published: 2012

Journal Articles

Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients

Michaela Rancea, Andreas Engert, MD, Peter Borchmann, MD, Bastian von Tresckow, MD, Teresa Halbsguth, MD, Karolin Behringer, MD, Diana Wongso, MD, Boris Böll, MD, Beate Klimm, MD, Indra Thielen, MD, Dennis A. Eichenauer, MD, Nicole Skoetz, MD

Blood (2012) 120 (21): 4230.

https://doi.org/10.1182/blood.V120.21.4230.4230

Published: 2012

Journal Articles

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Michael Fuchs, MD, Annette Pluetschow, Beate Klimm, MD, Teresa Halbsguth, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2011) 118 (21): 2711.

https://doi.org/10.1182/blood.V118.21.2711.2711

Published: 2011

Journal Articles

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

Bastian von Tresckow, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Denissa Peine, Stefan Knop, MD, Mariele Goebeler, MD, Jens M. Chemnitz, MD, Michael Hallek, MD, Andreas Engert, MD, Kai Hübel, MD

Blood (2011) 118 (21): 3965.

https://doi.org/10.1182/blood.V118.21.3965.3965

Published: 2011

Journal Articles

A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

Achim Rothe, MD, Anas Younes, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Dennis A. Eichenauer, MD, Joerg Kessler, Max S. Topp, MD, Horst Hummel, MD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Pogge von Strandmann, PhD, Andreas Engert, MD

Blood (2011) 118 (21): 3709.

https://doi.org/10.1182/blood.V118.21.3709.3709

Published: 2011

NARROW

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials

Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials

Systematic Review and Individual Patient Data Meta-Analysis Of Treatment-Related Risk Of Secondary Malignant Neoplasms After Hodgkin Lymphoma

A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients

A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only